间歇性偏头痛预防性治疗新药-Erenumab

Erenumab,a new drug for prevention of episodic migraine

Erenumab(商品名:Aimovig)是第1个获得FDA批准的新型偏头痛预防性治疗药物,主要通过阻断降钙素基因相关肽(Calcitonin gene-related peptide,CGRP)受体,抑制CGRP的活性而发挥作用。与传统治疗偏头痛急性期的药物相比,Erenumab可以有效预防慢性和间歇性偏头痛的发作,减少发作次数,且有良好的耐受性和较少的禁忌证。本文对Erenumab的作用机制、药动学、药效学、临床评价和安全性等方面进行综述,为临床治疗和深入研究提供参考。

Erenumab,with the brand name of Aimovig,is an antagonist of the Calcitonin Gene-Related Peptide Receptor(CGRP-receptor)which won the first approval of FDA for the treatment of episodic migraine by inhibiting CGRP activity.Compared with conventional drug for acute migraine,Erenumab can prevent the episode of chronic and intermittent migraine and reduce the episode times,which is better tolerated and has fewer contraindications.The article reviews the mechanism,pharmacokinetics,pharmacodynamics,clinical evaluation and safety of Erenumab,providing a reference for clinical treatment and further research.